AnaptysBio raises $208M following Phase IIa asthma readout

AnaptysBio Inc. (NASDAQ:ANAB) raised $207.8 million late Sept. 25 through the sale of 2.2 million shares at $94.46 in a follow-on underwritten by Credit Suisse, J.P.

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE